Seranova Bio
New Haven
About Seranova Bio
Seranova Bio partners with clinicians and drug developers to develop companion diagnostics or therapeutics to treat autoimmune disease or other autoantibody-driven diseases. The company's REAP platform was developed to detect autoantibodies that recognize “conformational” protein epitopes (i.e., three-dimensional epitopes present when a protein is folded into its native state) which are recognized by up 90% of autoantibodies. The platform includes over 3000 extracellular and secreted proteins to comprehensively characterize autoantibody responses in patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.0M
- Last round: Series Unknown (Feb 2024)
- Website: seranovabio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/seranova-bio-51753 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.